Add to ORKGThe Medicare Prescription Drug, Improvement, and Modernization Act (MMA) expressly forbids the Secretary of Health and Human Services (HHS) from negotiating the price of prescription drugs on behalf of Medicare beneficiaries. This report outlines the arguments for and against allowing the federal government to negotiate prescription drug prices on behalf of Medicare beneficiaries. This report will be updated, as needed
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that Med...
Prescription drugs are significantly more expensive in the United States than other countries. To r...
Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform ef...
The cost of brand-name drugs in the United States is up to four times higher than in other countries...
The U.S. is a relatively free-pricing market for pharmaceutical manufacturers to set list prices at ...
Testimony issued by the Government Accountability Office with an abstract that begins "Rising prescr...
Under the 2022 Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) are abl...
Testimony issued by the General Accounting Office with an abstract that begins "The pricing of Medic...
Nearly 30 percent of American adults report not taking medication because of its high cost. Compared...
The Medicare Modernization Act (MMA) prohibited the government from negotiating drug prices, a featu...
Mckenzie Taylor continues our monthly conversation on the strategies presented in The Trump Administ...
This article discusses the recent passage of the Medicare Prescription Drug, Modernization and Impro...
Efforts to enact a prescription drug benefit in Medicare date back more than forty years. Since then...
In recent years, drug manufacturers and private payers have expressed interest in novel pricing mode...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that Med...
Prescription drugs are significantly more expensive in the United States than other countries. To r...
Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform ef...
The cost of brand-name drugs in the United States is up to four times higher than in other countries...
The U.S. is a relatively free-pricing market for pharmaceutical manufacturers to set list prices at ...
Testimony issued by the Government Accountability Office with an abstract that begins "Rising prescr...
Under the 2022 Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) are abl...
Testimony issued by the General Accounting Office with an abstract that begins "The pricing of Medic...
Nearly 30 percent of American adults report not taking medication because of its high cost. Compared...
The Medicare Modernization Act (MMA) prohibited the government from negotiating drug prices, a featu...
Mckenzie Taylor continues our monthly conversation on the strategies presented in The Trump Administ...
This article discusses the recent passage of the Medicare Prescription Drug, Modernization and Impro...
Efforts to enact a prescription drug benefit in Medicare date back more than forty years. Since then...
In recent years, drug manufacturers and private payers have expressed interest in novel pricing mode...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that Med...
Prescription drugs are significantly more expensive in the United States than other countries. To r...